The differences between Apoe mRNA levels in CKD compared to AKI models (also see30) suggest a potential value to explore urinary levels of APOE, together with TIMP-2, IGFBP7 and other proteins, to develop composite biomarkers of AKI-to-CKD progression. This evidence concerns the gene TIMP2 and chronic kidney disease.